Search is Powered by Google
Cancer / Oncology News

Dynamics Of Conserved Waters In Human HSP 90: Implications For Drug Design

Main Category: Cancer / Oncology
Also Included In: Biology / Biochemistry
Article Date: 02 Oct 2008 - 7:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Water is known to be a potential mediator between a drug and its receptor but to what extent must it be considered to be essentially part of the active site and should a putative drug try to expel it.

Here we probe the dynamic behaviour of several water molecules that are predicted to persist in the active site of a potential anti-cancer site.

We find that they are not easily replaced and so further attempts to design drugs against this target must consider the plus-water surface.

Journal of the Royal Society Interface

Journal of the Royal Society Interface
is the Society's cross-disciplinary publication promoting research at the interface between the physical and life sciences. It offers rapidity, visibility and high-quality peer review and is ranked fifth in JCR's multidisciplinary category. The journal also incorporates Interface Focus, a peer-reviewed, themed supplement, each issue of which concentrates on a specific cross-disciplinary subject.

Journal of the Royal Society Interface




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

customize your homepage

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...